Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;43(10):2330-2332.
doi: 10.2337/dci20-0039.

The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients

Simeon I Taylor  1
Affiliations
Comment

The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients

Simeon I Taylor. Diabetes Care. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Impact of rebates. Panel A illustrates the complex supply chain for a drug such as insulin. PBMs require manufacturers to pay rebates in exchange for favorable placement of their drug in the PBM’s formulary. While the PBM retains a portion of the rebate, a substantial portion is paid to the health plan or insurance company, thereby decreasing the net cost of the drug paid by that health plan/insurance company. Panel B illustrates the impact of rebates on price paid for insulin during the decade between 2007 and 2016. While the list price has increased by 252% throughout the entire decade, the net price (equal to the list price minus rebates and discounts) has risen by only 57% over the entire time period and actually decreased between 2014 and 2016. The figures are reproduced with permission from Cefalu et al. (14).
See this image and copyright information in PMC

Comment on

References

    1. Nathan DM, Genuth S, Lachin J, et al. .; Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865 - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853 - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653 - PMC - PubMed
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589 - PubMed

Publication types